advertisement
Abstract #18361 Published in IGR 3-3
A comparison of intraocular pressure-lowering effect of prostaglandin F2α analogues, latanoprost, and unoprostone isopropyl
Kobayashi H; Kobayashi K; Okinami SJournal of Glaucoma 2001; 10: 487-492
PURPOSE: To compare the intraocular pressure (IOP)-lowering effect of unoprostone isopropyl (unoprostone) 0.12% and latanoprost 0.005%. A correlation between the IOP-lowering effect of unoprostone and latanoprost was also evaluated. METHODS: A single-masked randomized study included 18 patients aged between 49 and 68 years (mean, 60.7 ± 5.1 years) with an IOP in both eyes of from 21-27 mmHg. The patients were prospectively randomized to receive latanoprost in the right eye and unoprostone in the left, or unoprostone in the right eye and latanoprost in the left. The patients were followed up for eight weeks. This study evaluated the IOP-lowering effect and incidence of drug-related side-effects. RESULTS: Mean baseline IOP was 22.8 ± 1.2 mmHg in latanoprost-treated eyes and 22.4 ± 1.0 mmHg in unoprostone-treated eyes; there was no statistically significant difference between these groups. Mean IOP at eight weeks after the start of the administration was 16.7 ± 2.0 mmHg in latanoprost-treated eyes and 19.0 ± 1.5 mmHg in unoprostone-treated eyes. Patients in the latanoprost-treated group showed a greater IOP reduction compared with those in the unoprostone-treated group. Mean IOP changes in latanoprost-treated eyes were significantly greater at every visit (p < 0.0001). A change of IOP at eight weeks in the latanoprost-treated eyes was significantly correlated with that in the contralateral unoprostone-treated eyes (r = 0.665, p = 0.0013). There was no significant difference in the rate of ocular side-effects between latanoprost- and unoprostone-treated eyes. CONCLUSIONS: Latanoprost appears to have a more beneficial effect for IOP control compared with unoprostone. An IOP reduction in the latanoprost-treated eyes was significantly correlated with that in the contralateral unoprostone-treated eyes. There was no significant difference in the incidence of ocular side-effects between both drugs. Further investigation using more cases and longer follow-up periods are needed.
Dr H. Kobayashi, Department of Ophthalmology, Saga Medical School, Saga, Japan
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
